a few patients remain severely affected by atopic dermatitis into adult life despite treatment with systemic steroids azathioprine and photochemotherapy33 patients took part in a doubleblind placebocontrolled crossover study to assess the efficacy and safety of cyclosporin 5 mgkg per day in adults with severe refractory atopic dermatitistreatments were given for eight weeks each with one group n  16 receiving placebo followed by cyclosporin and another n  17 receiving cyclosporin and then placebodisease activity extent of disease sleep and itch topical steroid use and adverse events were assessed every two weeksboth extent and activity of dermatitis were significantly improved p less than 0001 as were subjective measures of disease20 patients receiving cyclosporin reported adverse events compared with 8 taking placebo although no patient required withdrawal from the studycyclosporin therapy led to an increase in the mean serum urea creatinine and bilirubin concentrations although only the rise in bilirubin was significant p  0001our results confirm that cyclosporin is a safe and effective shortterm treatment for severe refractory atopic dermatitis